Advertisement

Topics

Relvar Ellipta

17:14 EST 22nd November 2017 | BioPortfolio

Relvar Ellipta (FF/VI) is the first once-daily, inhaled corticosteroid/long-acting beta agonist (ICS/LABA) combination for the regular treatment of asthma in adults and adolescents aged 12 years and older approved in Japan. Relvar Ellipta contains the ICS fluticasone furoate (FF) and the LABA vilanterol (VI) and may be prescribed in two doses – 100/25 mcg and 200/25 mcg. Both dosages are administered using the Ellipta, a new dry powder inhaler (DPI).

For further information open http://www.gsk.com/

Quick Search
Advertisement
 

review and buy Relvar Ellipta market research data and corporate reports here